Search - tctmd.com

Displaying 1 - 20 of 205

Sort: Relevancy | Date

News Daily News

SURPASS-CVOT Published: Large Trial Confirms CVD Efficacy of Tirzepatide

Michael O'Riordan

December 18, 2025

News Daily News

Patients With Obesity Get Biggest Benefit from Evolocumab: FOURIER

Michael O'Riordan

December 12, 2025

News Daily News

Semaglutide’s CV Effects Only Partially Tied to Weight Loss: SELECT Analysis

Yael L. Maxwell

October 24, 2025

News Daily News

Oral Semaglutide Gets FDA Approval for CV Event Reduction in High-risk Diabetes Patients

Caitlin E. Cox

October 22, 2025

News Daily News

Pregnancy-Related CV Complications on the Rise

Todd Neale

October 09, 2025

News Daily News

Evolocumab Wins for Primary Prevention in VESALIUS-CV

L.A. McKeown

October 03, 2025

News Daily News

Better Outcomes and Lower Cost with Bariatric Surgery Over GLP-1s

Michael O'Riordan

September 18, 2025

News Daily News

AI Tool Supports Mammograms as Method to Screen Women for CV Risk

Caitlin E. Cox

September 18, 2025

News Daily News

Evolocumab Gains Expanded Indication for Primary Prevention

Michael O'Riordan

August 26, 2025

News Daily News

DAPT De-escalation Success Varies by Sex: Meta-analysis

Yael L. Maxwell

August 21, 2025

News Daily News

Inclisiran Gains Indication as Stand-alone Therapy to Reduce LDL Cholesterol

Michael O'Riordan

August 06, 2025

News Daily News

Glipizide, Commonly Used Sulfonylurea, Linked to Greater CV Risks

Michael O'Riordan

August 01, 2025

News Daily News

Tirzepatide Matches Dulaglutide in Large CV Outcomes Trial: SURPASS-CVOT

Michael O'Riordan

July 31, 2025

News Daily News

No Clarity on Colchicine: Two Meta-analyses Spark Debate on Drug’s Merits

Michael O'Riordan

July 14, 2025

News Daily News

Novel Calcium Score Accounting for Density and Location Ups MACE Prediction

Yael L. Maxwell

July 11, 2025

News Daily News

CV Risk Modest for Most Cancer Survivors in Large Danish Registry

L.A. McKeown

June 17, 2025

News Daily News

GLP-1s Reduce Limb and Cardiac Events in Peripheral Artery Disease

L.A. McKeown

June 12, 2025

News Daily News

Inclisiran Plus Usual Care Improves LDL Control in ACS: VICTORION-INCEPTION

Michael O'Riordan

June 04, 2025

News Daily News

Knowledge of Genetic Risk for CAD Bolsters Prevention, Reduces MACE

Caitlin E. Cox

April 23, 2025

Advertisement

SURPASS-CVOT Published: Large Trial Confirms CVD Efficacy of Tirzepatide

Patients With Obesity Get Biggest Benefit from Evolocumab: FOURIER

Semaglutide’s CV Effects Only Partially Tied to Weight Loss: SELECT Analysis

Oral Semaglutide Gets FDA Approval for CV Event Reduction in High-risk Diabetes Patients

Pregnancy-Related CV Complications on the Rise

Evolocumab Wins for Primary Prevention in VESALIUS-CV

Better Outcomes and Lower Cost with Bariatric Surgery Over GLP-1s

AI Tool Supports Mammograms as Method to Screen Women for CV Risk

Evolocumab Gains Expanded Indication for Primary Prevention

DAPT De-escalation Success Varies by Sex: Meta-analysis

Inclisiran Gains Indication as Stand-alone Therapy to Reduce LDL Cholesterol

Glipizide, Commonly Used Sulfonylurea, Linked to Greater CV Risks

Tirzepatide Matches Dulaglutide in Large CV Outcomes Trial: SURPASS-CVOT

No Clarity on Colchicine: Two Meta-analyses Spark Debate on Drug’s Merits

Novel Calcium Score Accounting for Density and Location Ups MACE Prediction

CV Risk Modest for Most Cancer Survivors in Large Danish Registry

GLP-1s Reduce Limb and Cardiac Events in Peripheral Artery Disease

Inclisiran Plus Usual Care Improves LDL Control in ACS: VICTORION-INCEPTION

Knowledge of Genetic Risk for CAD Bolsters Prevention, Reduces MACE

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content